Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

11 Oct 2017

Abstract excerpt

The NLRP3 inflammasome has been implicated in the pathogenesis of a wide variety of human diseases. A few compounds have been developed to inhibit NLRP3 inflammasome activation, but compounds directly and specifically targeting NLRP3 are still not available, so it is unclear whether NLRP3 itself can be targeted to prevent or treat diseases. Here we show that the compound CY-09 specifically blocks NLRP3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gout, Hyperuricemia, Uric Acid
Share to Inflammasome and immune disorders
Share to Sphingolipid Metabolism and Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29021150
DOI: 10.1084/jem.20171419

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disordersPMID 29021150Read ↗

The NLRP3 Inflammasome as a Pharmacological TargetSemantic proximity Read ↗

Anti-NLRP3 Inflammasome Natural Compounds: An UpdateSemantic proximity Read ↗

A patent review of NLRP3 inhibitors to treat autoimmune diseasesSemantic proximity Read ↗

Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseasesSemantic proximity Read ↗

Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease ModelsSemantic proximity Read ↗

Discovery of a Potent and Selective Inhibitor of Human NLRP3 with a Novel Binding Modality and Mechanism of ActionSemantic proximity Read ↗

A new lead to NLRP3 inhibitionSemantic proximity Read ↗

New Potentiality of Bioactive Substances: Regulating the NLRP3 Inflammasome in Autoimmune DiseasesSemantic proximity Read ↗

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibitionSemantic proximity Read ↗

MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibitionSemantic proximity Read ↗

Discovery of alantolactone as a naturally occurring NLRP3 inhibitor to alleviate NLRP3‐driven inflammatory diseases in miceSemantic proximity Read ↗

The discovery of NLRP3 and its function in cryopyrin‐associated periodic syndromes and innate immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.